ArticleInvestigative ophthalmology & visual science2025
Clinical and Molecular Landscape of GLRA2 in X-Linked Early-Onset High Myopia.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Multilevel Genetic and Functional Assessment of an ARR3 Frameshift Variant in Early-Onset High Myopia.International journal of genomics · 2026Article
- Establishing and validating a predictive model for long-term control outcomes following orthokeratology lenses wear: a five-year cohort study.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Variants in the GLRA2 gene have been linked to early-onset and nonsyndromic high myopia with a X-linked inheritance. This study aimed to elucidate clinical and genetic characteristics of GLRA2-associated early-onset high myopia (eoHM). Methods: Variants in 17 genes reported to contribute to eoHM, including GLRA2, were evaluated for pathogenic level based on in silico prediction, associated phenotypes, and cosegregation analysis. The available clinical data of individuals were summarized. Minigene constructs were generated to assess the effects of the variant c.494+1G>A in GLRA2 on splicing. We integrated previous evidence to curate the clinical validity of GLRA2 and eoHM using the ClinGen framework. Results: Pathogenic and likely pathogenic variants in 7 of 17 genes were identified in 47 of 389 probands with eoHM, including 21 in OPN1LW, 12 in ARR3, and 9 in GLRA2. For GLRA2, 15 pathogenic variants (10 missense and 5 truncation) were identified in 16 families, in whom probands had eoHM by X-linked inheritance. The average refraction was -9.76 diopters (D) (standard deviation: ±5.45 D). Central corneal thickness averaged 539.41 and 544.06 µm in the right and left eyes, respectively, with no or mild myopic retinal changes observed in 64.3% (27/42) of eyes. Posterior staphyloma was detected in 17 of 33 eyes (51.5%), with 6 eyes progressing to macular splitting. Most cases showed normal retinal sensitivity and stable fixation. Based on genetic and experimental evidence, the GLRA2-eoHM relationship was classified as "strong." Conclusions: This research expanded the mutational spectrum of GLRA2 and reveals GLRA2 as the third most frequently implicated gene for Mendelian eoHM. Truncations and highly scored missense variants in GLRA2 are pathogenic. Myopia due to GLRA2 mutations is transmitted in X-linked inheritance, manifests with mild cone impairment, and progresses to pathologic myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.